| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86dbece74d64d4ae1ce65b2c72199520
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d39ea9db0f9f5b12797508a366f43e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56c3891ce9cbfc7445b74d6c3a844e17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73d55b44219a84c850812a4488def924
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93c95221d4ce271c9989c0a7ed2124f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3905ae793263a4d081a74acedc6fb65e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-056 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 |
| filingDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d2096e34e8fd0b2dea965dbb8473c1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97901b67c180a77cd295d3a74d617862
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38d18282fbda4ff49238b890d78f73c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a19d5a9b2cb60cd1d8b93b6b1d5c298
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77c3ccd70d5760475b64c28e95122235 |
| publicationDate |
2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007099652-A1 |
| titleOfInvention |
Pharmaceutical composition for treatment of blood clotting disorder |
| abstract |
Disclosed is a pharmaceutical composition for the prevention or treatment of blood clotting disorder which can reduce a burden on a patient. The pharmaceutical composition comprises an effective amount of ribavirin or a derivative thereof or a pharmaceutically acceptable salt of ribavirin or the derivative. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009028575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009028573-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2009028575-A1 |
| priorityDate |
2006-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |